Skip to content

Intervention Study to Investigate the Effects of ONS Use Among Malaysian Children With Faltering Growth

A Randomised, Open Label, Controlled Intervention Study to Investigate the Effects Oral Nutritional Supplement in Malaysian Children With Faltering Growth

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05193630
Acronym
MONS
Enrollment
172
Registered
2022-01-18
Start date
2022-07-07
Completion date
2023-08-30
Last updated
2022-08-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Faltering Growth

Brief summary

A randomised, open label, controlled intervention study to test the effect of the test product with dietary counselling versus dietary counselling alone on Weight-for-Age z-score change in children from ≥ 1 to ≤ 6 years of age with faltering growth for duration of 12 weeks.

Detailed description

Parent(s) of potentially eligible subjects will be informed about the study and what is expected in case of participation to the study. Information on the study is incorporated in the Respondent's Information Sheet (RIS). The parent(s) will be given sufficient time to read and understand the Information Sheet and to ask questions. Parent(s) of eligible subjects will be approached at the main study clinic or they may be referred from one of the 'satellite clinics'. In case of referral, they will be pre-screened at the satellite clinic and if considered potentially eligible for the MONS study, they will be referred to the main study clinic for full screening. If subjects fulfil all inclusion and exclusion criteria, and if the parent(s) is (are) willing that his/her/their child will participate, he/she/they will be asked to sign the Informed Consent Form (ICF). Baseline evaluation (including history and anthropometric measurement) will be completed prior to randomisation. A block randomisation will be performed to allocate subjects to treatment arm or control arm in 1:1 ratio. At enrolment, the investigator assesses baseline characteristics, anthropometrics, appetite score, and the number of the child's sick days during the 4 weeks before enrolment. At the end of the visit, the investigator will provide two 3-days feeding diaries (one for baseline and one for Visit 2) and explain how and when these should be completed. The investigator will provide the Milnutri Sure™ product to the parent whose child is in the treatment arm, explain how to use the Milnutri Sure™ and how to apply other feeding advices for the coming 4 weeks until the next visit. For parent whose child is in the control arm, no Milnutri Sure TM product will be given, nevertheless, dietary counselling will be provided by the investigator. Four, eight and twelve weeks after enrolment, subjects will have clinic visits (Visit 2, 3 and 4) and the anthropometrics, adverse events, appetite score, compliance, and the number of the children's sick days since last visit will be assessed. At the end of the visit the investigator will provide the product to the parents whose children are in the treatment arm, explains how to use it and how to apply other feeding advices for the coming 4 weeks until the next visit. For parents whose children are in the control arm, though no Milnutri Sure TM product will be given, dietary counselling will be provided by the investigator. At week eight (Visit 3), the investigator will also provide a 3-days feeding diary to the parents to be completed just before the twelve-week 12 visit (Visit 4). In addition to this, at Visit 4 (the End of Study visit after 12 weeks in the study) the investigator will fill out the end of study visit requirements and stops providing study product. The investigator may request for a follow-up visit to monitor and provide medical and dietary counselling to the subject. If necessary, the investigator may prescribe Milnutri Sure ™ or any other growing up milk or nutritional counselling as part of normal practice.

Interventions

DIETARY_SUPPLEMENTMilnutri Sure™

Milnutri Sure™, a commercially available oral nutritional support (ONS) product in powder format, for children of 1 y of age and above (1.0 kcal /ml). For children between 1 and 3 years of age, the recommendation is to use 2 servings per day, and for children from 4 to 6 years of age, the recommendation is to give 3 servings per day. One serving contains of 45 grams of product and 180 ml water.

Sponsors

Universiti Putra Malaysia
CollaboratorOTHER
Danone Specialized Nutrition (M) Sdn Bhd
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Masking description

The anthropometric outcomes will be blinded to assessors and analyst until at least the primary outcomes have been analysed to reduce bias.

Intervention model description

A randomised, open label, controlled intervention study

Eligibility

Sex/Gender
ALL
Age
1 Years to 6 Years
Healthy volunteers
No

Inclusion criteria

1. Age: ≥1 and ≤ 6 years of age. 2. Weight at baseline between ≥ -3 and \< -1 SD WHO-score (mild to moderate undernutrition). 3. Informed consent provided.

Exclusion criteria

1. Underlying medical illness affecting growth, according to the clinician's opinion 2. Known lactose intolerance / cow's milk allergy 3. Use of (other) ONS 1+ (1 kcal/mL) at enrolment and/or during the three months before enrolment 4. Other family member is already participating in this MONS study. 5. Insufficient ability to understand or communicate in English and/or Bahasa Malaysia 6. Participating in any other clinical study

Design outcomes

Primary

MeasureTime frameDescription
Weight for Age (WAZ) score of the subject12 weeksderived from weight and age

Secondary

MeasureTime frameDescription
Weight for Height (WHZ) score, weight and height of the subject12 weeksderived from height and weight
(Serious) Adverse Events of the IP and possible relatedness to study12 weeksNumber, type and severity of (Serious) Adverse Events and possible relatedness to study product
Appetite score12 weeksAppetite score according to a visual analogue scale (0-10)
Nutritional intake12 weeksTotal energy intake and nutrient intake from solid food
Percentage of compliance12 weeksPercentage of compliance via missed servings compared to expected servings on product intake

Other

MeasureTime frameDescription
Number of sick days12 weeksNumber of sick days assessed via the investigator, who, at each clinic visit, asks the parents for the number of sick days during the past 4 weeks.

Countries

Malaysia

Contacts

Primary ContactZurina Zainudin
zaizurina@upm.edu.my+6012-2642174
Backup ContactDiana Rashid
diana.rashid@questra.com.my+6013-4619940

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026